

Title (en)  
HETEROCYCLIC AMINES FOR TREATING ISCHAEMIC STROKES

Title (de)  
HETEROCYCLISCHE AMINE ZUR BEHANDLUNG ISCHAEMIC HERZANFÄLLE

Title (fr)  
AMINES HETEROCYCLIQUES POUR LE TRAITEMENT DES ACCES ISCHEMIQUES

Publication  
**EP 0724577 A1 19960807 (EN)**

Application  
**EP 94929558 A 19941018**

Priority  
• EP 9403425 W 19941018  
• GB 9321811 A 19931022

Abstract (en)  
[origin: WO9511238A1] Use of compounds of formula (I), wherein R<1> and R<2> each independently represent: hydrogen, C1-8alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-4alkyl, arylC1-4alkyl, C2-6hydroxyalkyl or R<3>R<4>NC2-6alkyl (where R<3> and R<4> independently represent H or C1-4alkyl) or NR<1>R<2> represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR<5> (where R<5> is H, C1-4alkyl or arylC1-4alkyl), which ring may optionally be substituted by one or two substituents selected from C1-6alkyl and C1-6alkoxy; X represents O, S, or C=O; n is 5 to 11; and Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, C1-8alkyl, C1-8alkoxy, C1-2alkylenedioxy, e.g. methylenedioxy, trifluoromethyl, trifluoromethoxy, or by a group Ph(Alk<1>)pA(Alk<2>)q- where Ph is optionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk<1> and Alk<2> independently represent C1-4alkyl which may be straight or branched and p and q are independently 0 or 1 provided that the length of -(Alk<1>)pA(Alk<2>)q- does not exceed 5 atoms, or Ar is an optionally substituted tricyclic heteroaryl group (a), in which Y<1> is Y<2>(CH2)r where r is 0 or 1 and Y<2> is O, S or NR<6> where R<6> is hydrogen or C1-4alkyl, Z is (CH2)s or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; with the provisos that (i) when X is O or S, and NR<1>R<2> represents a heterocyclic ring which does not contain an optional further heteroatom then Ar is phenyl substituted by a group Ph(Alk<1>)pC(O)(Alk<2>)q-; (ii) when n is 5 and one of R<1> and R<2> is hydrogen, C1-4alkyl or arylC1-4alkyl, then the other of R<1> and R<2> is not R<3>R<4>NC2-6alkyl; and pharmaceutically acceptable salts thereof; in the manufacture of a medicament for the treatment of a condition where a calcium antagonist is required. Certain novel compounds of formula (I) and processes for preparing them are also described.

IPC 1-7  
**C07D 295/088; A61K 31/435; C07C 217/54; A61K 31/495; A61K 31/525**

IPC 8 full level  
**A61K 31/135** (2006.01); **A61K 31/445** (2006.01); **A61K 31/495** (2006.01); **A61K 31/535** (2006.01); **A61K 31/5375** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 25/28** (2006.01); **C07C 43/225** (2006.01); **C07C 43/295** (2006.01); **C07C 217/20** (2006.01); **C07D 295/08** (2006.01); **C07D 295/092** (2006.01); **C07D 295/108** (2006.01)

CPC (source: EP)  
**A61K 31/135** (2013.01); **A61K 31/445** (2013.01); **A61K 31/495** (2013.01); **A61K 31/535** (2013.01); **A61P 9/08** (2017.12); **A61P 9/10** (2017.12); **A61P 25/04** (2017.12); **A61P 25/06** (2017.12); **A61P 25/28** (2017.12); **C07C 217/20** (2013.01); **C07D 295/088** (2013.01); **C07D 295/108** (2013.01); **C07C 2601/08** (2017.04)

Citation (search report)  
See references of WO 9511238A1

Designated contracting state (EPC)  
BE CH DE FR GB IT LI NL

DOCDB simple family (publication)  
**WO 9511238 A1 19950427**; AU 7856694 A 19950508; EP 0724577 A1 19960807; GB 9321811 D0 19931215; JP H09504016 A 19970422; ZA 948233 B 19950725

DOCDB simple family (application)  
**EP 9403425 W 19941018**; AU 7856694 A 19941018; EP 94929558 A 19941018; GB 9321811 A 19931022; JP 51132195 A 19941018; ZA 948233 A 19941020